Lepu Medical's 2020 plan: precision medicine + in vitro diagnosis of chronic disease management dreams come true

Rooted in the cardiovascular market of 100 billion, the layout of a new blue sea: China's cardiovascular disease has "high incidence, high disability rate, high mortality, high recurrence rate, more complications" and other characteristics, Chinese residents for the cardiovascular field The demand for medicines, devices and medical services is huge. The rapid development of Lepu Medical benefits from the rapid expansion of the cardiovascular market in China. The construction of a three-level cardiovascular network medical service system provides a channel for the company's drugs and devices, and also provides flow support for the company's cardiovascular chronic disease management platform. Lepu Medical is expected to develop into a cardiovascular industry-wide industrial chain platform with a market value of 100 billion. However, cardiovascular disease can be interfered and prevented through lifestyle changes. It is believed that with the increasing health awareness of Chinese residents and the increasing popularity of cardiovascular disease screening and detection technologies, the incidence and mortality of cardiovascular diseases in China are expected to be effectively controlled. . The prevention, diagnosis and life intervention of cardiovascular disease will become the development trend of the domestic cardiovascular field, which is also the important direction of the future layout of Lepu Medical. In addition, Lepu Medical also actively deployed cardiovascular disease-related diabetes, blood purification and other fields, laying the groundwork for the company to enter the new blue ocean.

Extensive mergers and acquisitions + small equity investment, rapid deployment of IVD: At present, the existing IVD companies of Lepu Medical include: Lepu Technology, Aidekang, Lepu Gene (Epson, Purin Gene), Eucalyptus, Ya Union, Health, Century, Quanterix and so on. At this stage, Lepu Technology, Aidekang and Yalian Baide's business enable Lepu Medical to have the integration advantages of IVD equipment and reagent development, production and sales channels. At the same time, Lepu Gene and Quanterix are committed to molecular diagnosis in cardiovascular disease. The application of tumor screening and diagnosis, non-invasive prenatal screening, will be the focus of the company's future development; participation in eucalyptus, source innovation and the establishment of the medical Kang Century team is committed to the field of chronic disease management, will also Become an important measure to enhance user stickiness in the future.

Based on the cardiovascular field, the development of the chronic disease management platform: Lepu Medical has formed a development model combining traditional technology with high-end technology through endogenous development and extensional mergers and acquisitions. Among them, the traditional technology business is based on the “reagent + instrument + channel” mode, and the high-throughput sequencing service forms an effective mode of “third-party diagnosis + data analysis”. In the field of chronic disease management, it has “hardware + hospital promotion entrance”. +Software + Data Processing", the management's clear thinking will become an important direction for the future development of Lepu Medical.

Others Medical Accessory Device

We're professional Others Medical Accessory Device manufacturers and suppliers in China, specialized in providing high quality medical instruments with reasonable price. We warmly welcome you to buy or wholesale bulk Others Medical Accessory Device for sale here and get quotation from our factory.

Others Medical Accessory Device,Medical Led Cold Light Source,Endoscopy Surgical Light,Endoscope Light Cable

Tonglu WANHE Medical Instrument Co., Ltd , https://www.tlvanhurhealth.com